Global Pulmonary Arterial Hypertension Market Size, Share, Growth Analysis, By Route of Administration(Oral, Intravenous), By Type(Branded and Generic) - Industry Forecast 2024-2031

Pulmonary Arterial Hypertension Market size was valued at USD 7.03 billion in 2021 and is poised to grow from USD 7.40 billion in 2022 to USD 10.65 billion by 2030, at a CAGR of 5.33% during the forecast period (2023-2030).

The market for pulmonary arterial hypertension is dominated by a small number of companies in terms of branded or patented medications. Gilead Sciences, Johnson & Johnson, United Therapeutics, and other companies are among them. To counter this, numerous pharmaceutical firms are launching generic versions of pulmonary arterial hypertension medications in an effort to enter the PAH market as a result of the increased number of patent expirations. 'Actelion Pharmaceuticals Ltd. (Switzerland)', 'Bayer AG (Germany)', 'United Therapeutics Corporation (United States)', 'GlaxoSmithKline plc (United Kingdom)', 'Gilead Sciences, Inc. (United States)', 'Pfizer, Inc. (United States)', 'Arena Pharmaceuticals, Inc. (United States)', 'Reata Pharmaceuticals, Inc. (United States)', 'SteadyMed Therapeutics, Inc. (United States)', 'Lung Biotechnology PBC (United States)', 'AstraZeneca plc (United Kingdom)', 'Bristol-Myers Squibb Company (United States)', 'Teva Pharmaceutical Industries Ltd. (Israel)', 'Liquidia Technologies, Inc. (United States)', 'Merck & Co., Inc. (United States)', 'Novartis AG (Switzerland)', 'Actelion Pharmaceuticals US, Inc. (United States)', 'Acceleron Pharma Inc. (United States)', 'Eli Lilly and Company (United States)', 'Bayer HealthCare Pharmaceuticals (United States)', 'Mallinckrodt Pharmaceuticals (United Kingdom)', 'Aadi Bioscience, Inc. (United States)'

A uncommon, progressive condition known as pulmonary arterial hypertension (PAH) is characterised by elevated blood pressure in the arteries that carry blood to the lungs. Globally, the prevalence of PAH is rising as a result of ageing populations, rising rates of risk factors like obesity, and improved diagnostic techniques. This is anticipated to increase demand for PAH remedies.

With advancements in technology and an improved understanding of the genetic basis of PAH, there is an increasing focus on developing personalized therapies for patients. Companies are investing in research and development to identify biomarkers that can be used to predict disease progression and response to treatment, and to develop therapies that target specific genetic mutations.

In 2022, North America held the biggest revenue share of over 40.0% in the market for pulmonary arterial hypertension. The sophisticated healthcare systems in the United States and Canada, which make it easier to get cutting-edge treatments, are to blame for the significant portion. Additionally, heightened awareness, a high prevalence of diagnoses, and favorable government measures assist the expansion of the business in this area. The rise of the local market is aided by the presence of significant companies and a carefully thought-out reimbursement system. The demand for advanced healthcare facilities for treating pulmonary arterial hypertension in the region is being driven by the increased prevalence of chronic and infectious diseases and the high diagnostic rate